Why the study?
LQTS patients display a spectrum of phenotypes with often unknown causes, prompting investigation into whether the endocannabinoid system modulates the cardiac KV7.1/KCNE1 channel.
Population
Ex-vivo guinea pig hearts and molecular models of KV7.1/KCNE1 channels
Comparison
Endocannabinoid exposure vs baseline or control conditions
Design
Preclinical laboratory study using two-electrode voltage clamp, molecular dynamics simulations, and ex-vivo heart models
Authors
Loading...
Endocannabinoids may modify LQTS phenotype; hypothesis-generating and requires prospective validation before clinical consideration.
Endocannabinoids like ARA-S enhance hKV7.1/KCNE1 channel function and can reverse drug-induced QT prolongation in preclinical models, suggesting a potential therapeutic avenue for Long QT Syndrome.
Hiniesto‐Iñigo et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: